Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Pipeline Review, H2 2016

  • ID: 4035464
  • Drug Pipelines
  • 27 pages
  • Global Markets Direct
1 of 5
Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Pipeline Review, H2 2016

Summary

‘Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Pipeline Review, H2 2016’, provides in depth analysis on Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted pipeline therapeutics.

The report provides comprehensive information on the Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
Certain sections in the report may be removed or altered based on the availability and relevance of data.
Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN)
- The report reviews Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) Overview

Therapeutics Development

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Products under Development by Stage of Development

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Products under Development by Therapy Area

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Products under Development by Indication

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Pipeline Products Glance

Early Stage Products

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Products under Development by Companies

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Products under Development by Universities/Institutes

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Molecule Type

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Companies Involved in Therapeutics Development

Phylogica Ltd

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Drug Profiles

Drug to Inhibit C-Jun for Endometriosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-36 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PYC-98 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Dormant Projects

Transcription Factor AP 1 (Activator Protein 1 or Proto Oncogene c Jun or V Jun Avian Sarcoma Virus 17 Oncogene Homolog or p39 or JUN) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Phylogica Ltd, H2 2016

Dormant Projects, H2 2016

Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Phylogica Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll